The Fitchburg-based company will use the funding to support further development of its bacteria-killing wound dressing product, a release shows.

“This award will fund a prospective human clinical trial of the novel antibiofilm matrix on donor site wounds in patients in need of autologous skin grafts,” Imbed Biosciences CEO Ankit Agarwal said in a statement. “We are honored to develop this advanced wound matrix for maximizing the readiness and performance of our warfighters in the field.”

Click here to read the full article.